Double pancreatic cancer survival by 2020

World Pancreatic Cancer Coalition (WPCC) and American Association for Cancer
Research (AACR) Pancreatic Cancer Special Conference brought together patient
advocacy groups and outstanding professionals 10-15 May, 2016 in Orlando,
Florida to discuss pancreatic cancer, a disease with the lowest survival rates
of any major cancer

Prof Borrebaeck presented in his AACR talk how serum biomarker signatures can
detect early stages of pancreatic cancer
LUND, Sweden - The days between 10 to 15 of May, 2016 were dedicated to the
deadliest form of cancer, pancreatic cancer, by two major events that took place
in Orlando, USA: the first World Pancreatic Cancer Coalition (WPCC) followed by
the third AACR Pancreatic Cancer Special Conference. Both events represented
major breakthroughs for Immunovia and IMMray™ PanCan-d as the following main
areas in pancreatic cancer were emphasized:

Firstly, the largest global patient advocacy pancreatic cancer coalition was
formed to provide a united front against this lethal disease. Immunovia sponsors
the patient advocacy world coalition and will work closely with the members on
both national and global levels.

Secondly, the main focus of pancreatic cancer care is now clearly early
detection of stages I & II for improved chances of patient survival. Prof
Borrebaeck’s talk presented clinical studies results covering over 2500
pancreatic cancer blood samples that show that IMMray™ PanCan-d can detect
stages I, II, III and IV patients with an accuracy of 98%. The Scandinavian
study that was finalized last year, was presented for the first time at this
event and the data (that were initially press released in Nov 2015:
link (http://immunovia.com/immray-pancan-d-detects-98-of-pancreatic-cancers-in
-retrospective-study-with-1400-blood-samples/)) showed that Immunovia’s test is
able to detect the early stages of pancreatic cancer in blood with unprecedented
accuracy of 96%. The talk received fantastic response from the conference
participants and particularly from Key Opinion Leaders.

Thirdly, the high risk group of late onset diabetes after 50 years of age was
strongly brought forward as an area that needs immediate and increased priority.
Immunovia has commenced discussions to participate in the late onset diabetes
programs underway.

To read the complete summary from the WPCC and AACR Pancreatic Cancer Special
Conference in Orlando, click here (PDF).


                                                                               2
0 
16-05-30

Laura Chirica, PhD, Immunovia, Sweden